Date:1/8/2009

picoplatin in combination with 5-fluorouracil and leucovorin (the FOLPI regimen) to oxaliplatin given in combination with 5-fluorouracil and leucovorin in the FOLFOX regimen. -- Present updated Phase 2 clinical data, including progression-free and overall survival data from this trial, at additional medical conferences. -- Present final Phase 1 FOLPI clinical data comparing once monthly and bi-weekly picoplatin administration at key medical conferences. Hormone-Refractory or Castration-Resistant Prostate Cancer -- Present data from the ongoing Phase 2 trial of picoplatin in patients with metastatic HRPC at ASCO's 2009 Genitourinary Cancers Symposium on February 27 in Orlando, Fla. This study is evaluating the efficacy and safety of picoplatin administered every three weeks in combination with full-dose docetaxel and daily prednisone as a first- line treatment in patients with metastatic HRPC or CRPC who have not received prior chemotherapy. PSA response (defined as a PSA reduction of at least 50 percent from baseline) is the primary endpoint, and secondary endpoints include safety, tumor response rate, time to progression and overall survival. -- Present updated Phase 2 clinical data, including time to disease progression and overall survival data, at additional medical conferences. Oral Picoplatin Program -- Present final data from the Phase 1 trial of orally vs. intravenously administered picoplatin in patients with advanced solid tumor malignancies at medical conferences.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin has
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Announces Upcoming Conference Participation
4. Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
5. Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
6. MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009
7. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
8. Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
9. Akrimax Pharmaceuticals Announces Manufacturing Partnership
10. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia